These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37089132)

  • 1. Sugar content and erosive potential of commonly prescribed Orodispersible tablets- An
    Anand L; Pentapati K; Shenoy R; Yelleti G; Kumar S
    F1000Res; 2023; 12():228. PubMed ID: 37089132
    [No Abstract]   [Full Text] [Related]  

  • 2. Erosive potential of sugar free and sugar containing pediatric medicines given regularly and long term to children.
    Arora R; Mukherjee U; Arora V
    Indian J Pediatr; 2012 Jun; 79(6):759-63. PubMed ID: 21830024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies.
    Atrux-Tallau N; Naimi Z; Jaudinot EO
    Clin Drug Investig; 2022 Dec; 42(12):1101-1112. PubMed ID: 36331670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V; Pabari RM; Kelly JG; Ramtoola Z
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil-Loaded Limonene-Based Orodispersible Tablets: Formulation, in vitro Characterization and in vivo Appraisal of Gastroprotective Activity.
    Mehanna MM; Mneimneh AT; Domiati S; Allam AN
    Int J Nanomedicine; 2020; 15():10099-10112. PubMed ID: 33363369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are sugars-free medicines more erosive than sugars-containing medicines? An in vitro study of paediatric medicines with prolonged oral clearance used regularly and long-term by children.
    Maguire A; Baqir W; Nunn JH
    Int J Paediatr Dent; 2007 Jul; 17(4):231-8. PubMed ID: 17559449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
    Hobbs D; Karagianis J; Treuer T; Raskin J
    Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food acid content and erosive potential of sugar-free confections.
    Shen P; Walker GD; Yuan Y; Reynolds C; Stacey MA; Reynolds EC
    Aust Dent J; 2017 Jun; 62(2):215-222. PubMed ID: 28107545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
    Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
    Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone.
    Tranová T; Loskot J; Navrátil O; Brniak W; Mužíková J
    Int J Pharm; 2023 Apr; 636():122838. PubMed ID: 36921743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits.
    Aljimaee YH; El-Helw AR; Ahmed OA; El-Say KM
    Drug Des Devel Ther; 2015; 9():1379-92. PubMed ID: 25834396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
    Kokott M; Lura A; Breitkreutz J; Wiedey R
    Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Evaluation of Orodispersible Tablets Containing Ketoprofen.
    Oliveira LJ; Veiga A; Stofella NCF; Cunha AC; da Graça T Toledo M; Andreazza IF; Murakami FS
    Curr Drug Deliv; 2020; 17(4):348-360. PubMed ID: 32183668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
    Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
    Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiologically-based drug absorption modeling for orally disintegrating tablets.
    Kambayashi A; Kiyota T
    Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.
    Tashan E; Karakucuk A; Celebi N
    AAPS PharmSciTech; 2020 Apr; 21(3):115. PubMed ID: 32296987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
    Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
    Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Marzouk MA; Osman DA; Mohamed OS
    Drug Dev Ind Pharm; 2021 Apr; 47(4):645-653. PubMed ID: 33826435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.